Initial reports of cases of PDAC began to emerge more than 10 years ago in relation to exenatide (Table 1) 32
Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, et al
In the current analysis, they saw no discernible effects on markers of subclinical vascular disease, including endothelial function and arterial stiffness, or on calcified atherosclerotic plaque
High frequency of BRAF mutations in nevi
To improve model stability at the lower boundary of the dose range, pseudo-observations corresponding to zero weight change at 0 mg were included for each drug
Verzola D, Picciotto D, Saio M, Aimasso F, Bruzzone F, Sukkar SG, et al